A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Soleo Health Chief Executive Officer Drew Walk Named to NHIA Board of Directors

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the appointment of Chief Executive Officer Drew Walk to the National Home Infusion Association (NHIA) 2023-2024 Board of Directors.

Drew Walk joins a group of seasoned home infusion experts on the NHIA board, an industry governing body. NHIA is the leading industry association providing education, information, advocacy and resources for the nation’s home and alternate site infusion provider community and the manufacturers, suppliers and service companies who support them. As a leading voice for the home infusion industry on Capitol Hill and with the Administration, NHIA advocates for the industry, ensuring that federal policy supports equitable access to the full range of home infusion therapies and related services.

“It is both a privilege and an honor to be asked to serve on NHIA’s Board of Directors alongside industry leaders and individuals who lead well-established and respected companies in the home infusion arena. I am proud to have an opportunity to add my voice to theirs as we work collectively to further the important role home infusion plays for all stakeholders – patients, payors, physicians, health systems and pharmaceutical manufacturers,” Walk said of his Board appointment.

“In my Board position, I hope to advance the key issues we face as an industry and find solutions that assist in enhancing patient care. These include, among others, addressing the changing regulatory landscape and reimbursement environment as well as facilitating technology across all communication channels including patient-provider and patient-pharmacy since the use of telehealth initiatives are on the rise,“ Walk concluded.

Connie Sullivan, BSPharm, NHIA president and chief executive officer, commented on Walk’s Board appointment: “We welcome Drew to the NHIA Board, which we expanded this term to 15 total seats to allow for broader diversification of infusion provider organization representation. Over the course of his career, Drew has worked with various types of healthcare entities which allows him to bring a broad range of experience to all stakeholders. We look forward to Drew’s contributions to our constituents and Board.”

The 2023-2024 Board of Directors will be installed after NHIA’s Annual Conference in Washington, D.C., March 25-29, 2023. Each will serve a three-year term.

Drew Walk has been involved in the home infusion industry since 1985. Trained as a pharmacist, he has held roles of increasing responsibility at health systems, small independent infusion pharmacies and large national providers. This directly speaks to the range and depth of his experience. Walk’s new appointment marks the second time he has served on the NHIA Board, the first being a four-year term from 2010-2014.

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Julie Blasingim, formerly President, has over 20 years of experience in the clinical research industry.
John Witkowski served as President of DSM Biomedical, the global biomaterials division of dsm-firmenich, where he led a significant period of transformational growth.
Julia James served as Executive Vice President and General Counsel of PPD, the leading contract research organization, until its acquisition by Thermo Fisher Scientific in 2021. She then continued as General Counsel, Clinical Research, following the transaction.

By using this website you agree to accept Medical Device News Magazine Privacy Policy